At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed how monoclonal antibodies transformed lymphoma treatment; Michel C. Nussenzweig, MD, PhD, of The Rockefeller University, explored...
Immunotherapy lowers risk for graft-versus-host disease, and women with cancer still lack crucial fertility preservation conversations.
The allogeneic regulatory T cell therapy was designed to improve HSCT outcomes in patients with hematological malignancies. The U.S. Food and Drug Administration (FDA) has approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem...
The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma recurrence, identifying patients with multiple myeloma who may benefit from debulking chemotherapy, examining considerable improvements...
A new report details persistent disparities in cancer care, and the FDA approved an antibody-drug conjugate as a first-line treatment for advanced triple-negative breast cancer.
At the AACR Annual Meeting 2026, a session highlighted progress from four Cancer Grand Challenges teams on the interplay of mutations, promoting factors, and tissue-specific epigenetic programs in cancer development and on the biology...
The AACR Cancer Disparities Progress Report 2026 included an examination of the growing gap in cancer care between rural and urban areas. The report also featured the stories of several cancer survivors—including Dennis Gruenhagen,...
Sacituzumab govitecan-hziy was approved as a monotherapy or in combination with pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for two indications in adult patients with unresectable locally advanced...
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration (FDA) has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), with or without pertuzumab (Perjeta),...
The cochairs of the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers—Andrew Futreal, PhD, FAACR, of The University of Texas MD Anderson Cancer Center; Taran Gujral, PhD, of Fred Hutch...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More